Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
about
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenLHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenChemotherapy in Premenopausal Breast Cancer PatientsAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineLong term side effects of adjuvant chemotherapy in patients with early breast cancerA small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.The effect of symptom clusters on functional status and quality of life in women with breast cancerEmerging gonadotropin-releasing hormone agonists.Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.Is Chemoendocrine Treatment without Alternative?Breast cancer in young women: special considerations in multidisciplinary care.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.Postoperative endocrine therapy for invasive breast cancer.Breast cancer in young womenAdjuvant ovarian suppression in premenopausal breast cancer.Benefits and adverse effects of endocrine therapyLong-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineTamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials.Changing concepts: Menopausal hormone therapy and breast cancer.Hormonal therapy for primary breast cancer: scientific rationale and status of clinical research.Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group reportAn accelerated failure time mixture cure model with masked event.Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.Selection of optimal adjuvant endocrine therapy for early-stage breast cancer.Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.Adjuvant hormonal therapy in premenopausal women with breast cancer.A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerPrognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.Controversies in preservation of ovary function and fertility in patients with breast cancer.A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancerAdjuvant endocrine therapies for premenopausal women.
P2860
Q24240015-5342C9F4-C443-4330-AC9C-9CA15EFE7407Q24240972-05350A3D-A3DC-465B-923A-F7A071DAAA76Q26774622-D4A7E5E6-F283-457E-A1B8-A1202AD3A01CQ27002430-9BCF1068-D305-488D-BCB6-D068173694C9Q28083233-4F95BFF1-5F3C-4508-9EA9-2EEEE0FE014BQ33402985-22809BB8-4301-4A35-AC46-15306BD1A94FQ33618137-04C7E5A3-2937-4038-9533-A3D85B086AE3Q33699302-A8950865-9D6B-4665-9CBE-F5B64FBE09F5Q33796122-877071E6-991F-413E-927A-1059C96C28C7Q33966418-F0D1C789-B305-4A60-9CEE-EB80D2B5351AQ34109991-84391704-364B-4306-9ED5-2DF296B19429Q34284263-FEA0E3A5-EDAD-4079-8384-6D221224C4EFQ34306522-EF2D32D2-F95A-4374-ACC3-6B060FCDAB12Q34315684-3A876A82-08BE-43A6-B0E3-21E0B92F00CEQ34334964-195D54B8-E183-45B3-A39D-BD0305C23115Q34351173-24F1C598-E596-43DA-8B3C-98BA7B69641AQ34611626-887E4DDD-1FC5-4D0A-B4A9-29173D534ACFQ34680563-5E590FC8-E935-46DB-9017-8C702F466694Q34877439-0460559D-1A89-4A50-AAB4-B5970D731DFEQ34910095-E7E67004-22E0-4F55-B0CA-108877D6268AQ34989073-EA0B4DDB-5A9F-4E8B-AB77-19D9A6DE1EDDQ35124558-F6EA835A-6E9F-48E9-8F42-AED6ACB27220Q35135718-9BA4174F-3BF1-4E3C-A98A-25C00C7E9E14Q35230269-70C61767-B39D-4894-80A5-E55534D73163Q35239634-BE2A9F17-59A0-464B-9734-42A3FC141BB6Q35673773-4DE9DB40-EC43-49B7-A5A3-E915BC24D923Q35866374-CB383D40-2275-47E9-AEC4-FCAF32CC1010Q35989728-89D965D9-45C0-4B63-841D-5240CF16625AQ36337766-2C918BD5-C50D-4B2D-807D-B39722CB4A20Q36346604-830B08EB-5A5C-4D65-9769-9603CA537FFEQ36360338-8C16E544-55ED-4419-BE8E-E9A77E1503A9Q36376841-8A7EA594-7E6E-4738-973A-748C4EDFED7FQ36385201-A1D153EB-8322-406C-A3FB-48CB8482DB5BQ36450218-000B6A3B-6745-4FC1-800A-22641166085FQ36457989-E1827579-078D-41E1-BCA3-C595AF2305EDQ36593931-6A3F1112-F080-4DDD-8E58-4D43A83C777DQ36658463-2BBEC264-F81B-4C3D-A0CB-0B9D15862F0CQ36801086-B91933D9-3B5F-421A-9833-D5F55793053DQ36820243-BC8639E0-8F23-4ECC-B672-FE250ED9BB81Q36862133-050305FA-A5DB-4151-A254-F36374F53123
P2860
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@en
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@nl
type
label
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@en
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@nl
prefLabel
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@en
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@nl
P2093
P2860
P356
P1476
Adjuvant chemotherapy followed ...... st cancer: a randomized trial.
@en
P2093
Alan S Coates
Anne O'Neill
Aron Goldhirsch
International Breast Cancer Study Group (IBCSG)
Karen N Price
M Laura Nasi
Marco Bonetti
Marco Colleoni
Monica Castiglione-Gertsch
Richard D Gelber
P2860
P304
P356
10.1093/JNCI/DJG119
P407
P577
2003-12-01T00:00:00Z